Key result
PDE2 regulates cardiovascular cAMP/cGMP crosstalk, emerging as a potential therapeutic target.
Why the study?
PDE2 regulates crosstalk between cAMP and cGMP pathways in the cardiovascular system, but its regulatory functions and prospective role as a therapeutic target in cardiovascular disorders require comprehensive overview.
This review highlights the regulatory functions of PDE2 in the cardiovascular system and its potential as a therapeutic target for cardiovascular diseases.
PDE2 modulation merits clinical investigation in cardiovascular disorders; leaves open confirmation via randomized trials before any practice change.
Phosphodiesterases (PDEs) are the principal superfamily of enzymes responsible for degrading the secondary messengers 3',5'-cyclic nucleotides cAMP and cGMP. Their refined subcellular localization and substrate specificity contribute to finely regulate cAMP/cGMP gradients in various cellular microdomains. Redistribution of multiple signal compartmentalization components is often perceived under pathological conditions. Thereby PDEs have long been pursued as therapeutic targets in diverse disease conditions including neurological, metabolic, cancer and autoimmune disorders in addition to numerous cardiovascular diseases (CVDs). PDE2 is a unique member of the broad family of PDEs. In addition to its capability to hydrolyze both cAMP and cGMP, PDE2 is the sole isoform that may be allosterically activated by cGMP increasing its cAMP hydrolyzing activity. Within the cardiovascular system, PDE2 serves as an integral regulator for the crosstalk between cAMP/cGMP pathways and thereby may couple chronically adverse augmented cAMP signaling with cardioprotective cGMP signaling. This review provides a comprehensive overview of PDE2 regulatory functions in multiple cellular components within the cardiovascular system and also within various subcellular microdomains. Implications for PDE2- mediated crosstalk mechanisms in diverse cardiovascular pathologies are discussed highlighting the prospective use of PDE2 as a potential therapeutic target in cardiovascular disorders.
No takes yet. Share an insight, caveat, or question.
Sadek et al. (2020) conducted a review in Cardiovascular Diseases. PDE2 targeted therapy was evaluated. PDE2 serves as an integral regulator for cAMP/cGMP pathway crosstalk in the cardiovascular system, highlighting its prospective use as a potential therapeutic target in cardiovascular disorders.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: